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Protocol
AbstrACt
Introduction Treatment-resistant schizophrenia (TRS) is 
a severe form of schizophrenia. In the European Union, 
approximately 40% of people with schizophrenia have 
TRS. Factors such as the persistence of positive symptoms 
or higher risk of comorbidities leave clinicians with a 
complex scenario when treating these patients. Intervention 
strategies based on mHealth have demonstrated their ability 
to support and promote self-management-based strategies. 
Mobile therapeutic attention for treatment-resistant 
schizophrenia (m-RESIST), an innovative mHealth solution 
based on novel technology and offering high modular and 
flexible functioning, has been developed specifically for 
patients with TRS and their caregivers. As intervention in 
TRS is a challenge, it is necessary to perform a feasibility 
study before the cost-effectiveness testing stage.
Methods and analysis This manuscript describes the 
protocol for a prospective multicentre feasibility study 
in 45 patients with TRS and their caregivers who will be 
attended in the public health system of three localities: 
Hospital Santa Creu Sant Pau (Spain), Semmelweis 
University (Hungary) and Gertner Institute & Sheba 
Medical Center (Israel). The primary aim is to investigate 
the feasibility and acceptability of the m-RESIST solution, 
configured by three mHealth tools: an app, wearable and 
a web-based platform. The solution collects data about 
acceptability, usability and satisfaction, together with 
preliminary data on perceived quality of life, symptoms 
and economic variables. The secondary aim is to collect 
preliminary data on perceived quality of life, symptoms 
and economic variables.
Ethics and dissemination This study protocol, funded by 
the Horizon 2020 Programme of the European Union, has 
the approval of the ethics committees of the participating 
institutions. Participants will be fully informed of the 
purpose and procedures of the study, and signed inform 
consents will be obtained. The results will be published 
in peer-reviewed journals and presented in scientific 
conferences to ensure widespread dissemination.
trial registration number NCT03064776; Pre-results.
IntroduCtIon 
background
In the European Union, between 0.2% and 
2.6% of the population suffer from psychotic 
disorders.1 The largest group is patients with 
schizophrenia, and around 20%–30% are 
patients whose condition does not respond 
satisfactorily to adequate treatment and 
clearly have harder-to-treat psychotic symp-
toms, despite adherence to current opti-
mised treatment.2 These patients are referred 
to as patients with treatment-resistant 
strengths and limitations of this study
 ► To the authors’ knowledge, mobile therapeutic 
attention for treatment-resistant schizophrenia 
(m-RESIST) is the first mHealth platform specifically 
addressed to treatment-resistant schizophrenia.
 ► The m-RESIST solution includes a sophisticated tool 
to detect early warning signs for preventing symp-
toms before they occur.
 ► This study promotes the involvement of the caregiv-
ers in the therapeutic process and a closer monitor-
ing and communication with clinicians.
 ► The outcomes of this study will help in future per-
formance of a cost-effectiveness randomised con-
trolled trial.
 ► The study focuses on feasibility and acceptability, so 
any differences found in outcomes should be treated 
with caution due to the design (small sample size, 
absence of control group, and  the short length of 
intervention and follow-up period).
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schizophrenia (TRS).3 4 TRS is a complex phenomenon 
influenced by a great variety of schizophrenia subtypes, 
psychiatric comorbidity and coexisting medical illnesses. 
Such patients pose a challenge to psychiatric and primary 
care clinicians, generating a financial burden on society 
due to frequent emergency visits, hospitalisations and 
chronic use of polypharmacy.5 Moreover, there is also a 
huge impact in human terms with regard to patients and 
caregivers, involving several dimensions such as quality 
of life, treatment side effects, caregiver burden, social 
impairment and high mortality.6 
Standard intervention in patients with TRS is chal-
lenging due to the persistence of positive symptoms, exten-
sive periods of hospitalisation and elevated risk of somatic 
and psychiatric comorbidities. Improvement obtained 
by current drug therapy, such as clozapine alone or in 
combination with another antipsychotic/mood stabiliser, 
is frequently not effective enough to achieve remission in 
patients with TRS.7 Therefore, the development of inno-
vative evidence-based interventions adjunctive to pharma-
cological and psychosocial treatment is needed.
Previous studies have shown feasibility, acceptability 
and also preliminary efficacy of mobile interventions 
(mHealth) for schizophrenia.8–14 Over 80% of partici-
pants indicated that they would recommend the interven-
tions and that they were easy to use and useful, reporting 
also high levels of satisfaction. Intervention strategies 
based on mHealth have demonstrated their ability to 
support and promote self-management-based strategies 
in psychotic disorders.
Mobile interventions may be effective in preventing 
relapses, increasing treatment adherence and relieving 
some of the symptoms, though the effects on social func-
tioning remain unclear.11 13 15 16 Smartphone ownership 
among people with schizophrenia is relatively high and 
increasing.17 Moreover, patients also seem to be willing 
and able to use smartphones to monitor their symptoms, 
engage in therapeutic interventions and increase physical 
exercise.9 Alvarez-Jimenez et al performed a meta-analysis 
of 12 studies, where evidence on acceptability, feasibility, 
safety and benefits of online and mobile-based inter-
ventions for psychosis were analysed.18 Results showed 
that 74%–86% of patients used web-based interventions 
efficiently, 75%–92% perceived them as positive and 
useful, and 70%–86% of patients completed or engaged 
with the interventions during follow-up. On the other 
hand, 26% of patients experienced difficulties in using 
web-based psychoeducation and cognitive behavioural 
therapy (CBT), the main causes being lack of motivation, 
poor engagement and poor understanding.18 It should 
be noted that the lack of published mHealth studies 
focusing on patients with TRS makes it more difficult to 
design novel interventions. Therefore, future mHealth 
studies in TRS should pay attention to some essential 
aspects: the recruitment process, the design and delivery 
of patient-centred and easy-to-use mHealth programmes, 
and strategies to maximise retention rates. Performing 
a feasibility study would be helpful to explore the 
acceptability and adequacy of intervention components, 
evaluate recruitment and assessment procedures, and to 
ensure if changes will be necessary during a subsequent 
cost-effectiveness randomised controlled trial (RCT).
This study protocol (version 1; dated 5 July 2016) 
is part of a European research project, cofunded by 
the Horizon 2020 Framework Programme of the Euro-
pean Union (grant agreement n° 643552). This project 
aims to develop and test the use of m-RESIST, a mobile 
system  based on information and communications tech-
nology (ICT), addressed to empower patients suffering 
from TRS and to involve their caregivers. This platform 
offers a holistic approach to integrate psychiatric and 
psychological assistance, offering a better monitoring 
of patients through a personalised and optimised ther-
apeutic process, promoting acceptance and self-manage-
ment of the condition, and potentiating a proactive role 
of patients and caregivers in the therapeutic process.
As stated by Aranda-Jan et al,19 the main considerations 
for an effective mHealth project are an appropriate 
project design (adapted to the local context), the avail-
ability of technology and resources, the involvement of 
stakeholders and the implementation process in health-
care systems. According to these conditions, a qualitative 
study about the receptivity of patients with TRS, caregivers 
and clinicians towards possible m-RESIST components 
was performed during the first stage of the m-RESIST 
solution development. The hypothetic positive accept-
ability of the solution in terms of usefulness, increase of 
patient’s empowerment and social contact promotion was 
shown.10
The current study protocol corresponds to the second 
stage of the project, aimed at ensuring that the designed 
solution satisfies the needs of end-users. To explore this, 
a feasibility study will be performed in an environment as 
close as possible to real-life settings, where the m-RESIST 
prototype will be tested in the target group (patients, 
caregivers and clinicians).
Aims and hypothesis
The objectives of this study are:
 ► To investigate rates of willingness to enrol, attrition 
(non-usage and dropout attrition) and compliance 
with the study.
 ► To investigate the acceptability of the m-RESIST solu-
tion in patients with TRS, caregivers and clinicians.
 ► To examine participants’ satisfaction and the usability 
of the m-RESIST solution.
 ► To explore the suitability and availability of proposed 
clinical, functional and economic outcomes measures.
The hypotheses are:
1. The m-RESIST solution will have acceptable rates of 
willingness to enrol (≥70%), non-usage and dropout 
attrition (both <15%) in patients with TRS.
2. The m-RESIST solution will be highly accepted by pa-
tients with TRS and reflected in high scores in accept-
ability, usability and satisfaction reported by more than 
80% of the patients.
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3. The proposed clinical, functional and economic out-
comes measures will be suitable and available for TRS.
MEthods And AnAlysIs
The following methods adhere to the Standard Protocol 
Items Recommendations for Interventional Trials 
(SPIRIT) guidelines for the reporting of study protocols.20
study design and setting
This is a prospective multicentre feasibility study, 
without a control group, following an iterative process in 
patients with TRS and their caregivers. Participants will 
be recruited from three sites: Gertner Institute & Sheba 
Medical Centre, Psychiatric Division (Tel Aviv, Israel); 
Semmelweis University, Department of Psychiatry and 
Psychotherapy (Budapest, Hungary), and Hospital de la 
Santa Creu i Sant Pau-D of Psychiatry (Barcelona, Spain). 
These sites provide full-spectrum mental health services 
to adult people from their catchment area and have wide 
experience in participating in large-scale clinical trials in 
patients with schizophrenia.
Participants
A total of 45 patients with TRS (15 per centre), with their 
caregivers, will be selected for invitation to participate by 
researchers. The eligibility for participation will be based 
on the inclusion and exclusion criteria in table 1.
Due to the voluntary nature of participation in clinical 
trials, participants may leave the study without having to 
specify their reasons. The investigators could also dismiss 
a participant from the study whenever they consider it 
appropriate.
Reasons for withdrawal include events such as inpatient 
psychiatric hospitalisation. A participant will be with-
drawn from the study participation if she/he:
 ► Refuses to cooperate.
 ► Wishes to drop out (in this instance a specific reason 
must be recorded by the investigator).
 ► Experiences adverse events sufficiently severe that, in 
the opinion of the investigator, it would be harmful to 
continue in the study.
 ► Has a general medical condition that, in the opinion 
of the investigator, would make it harmful to continue 
in the study.
 ► Does not complete the study as outlined in the study 
protocol.
Intervention
In the current study, the intervention will involve 
patients and their caregivers, and the main actors 
involved in the deployment of the m-RESIST solu-
tion will be a psychiatrist, a psychologist and a case 
manager. The key aim of the intervention delivered by 
the m-RESIST solution is to engage patients with TRS, 
together with their caregivers, in an active participation 
in therapeutic processes, and empower them to enable 
the self-management of their condition. To achieve 
this objective, the intervention is supported by three 
mHealth tools: a wearable (smartwatch), a mobile app 
and a web-based platform (see figure 1). Patient compli-
ance will be measured by the number of days that the 
m-RESIST was used during the 3 months of interven-
tion. Data for usage will be captured automatically by 
the m-RESIST software.
The functionality of the smartphone is based on the 
m-RESIST app. Through this app, patients will have access 
to educational content about TRS condition and related 
issues; track their early warning signs (EWSs), symptoms 
and biological variables; ask for help by questionnaires or 
the ‘alarm bottom’; receive and practice helpful CBT-based 
Table 1 Inclusion and exclusion criteria for the study
Inclusion criteria Exclusion criteria
1. Patients with age between 18 and 45 years with a diagnosis 
of schizophrenia according to DSM-V criteria.
2. Duration of disease <15 years.
3. Meet criteria for TRS.*
4. Used to ICT tools and physical capability to use them.
5. Presence (and willingness to participate) of a caregiver or 
informal carer.
1. Meet criteria for remission according to the Remission of 
Schizophrenia Working Group.23
2. Presence of delusions mainly related with their therapists or 
with new technologies.
3. To have hearing, vision or motor impairment that makes 
impossible to operate a smartphone.
4. The caregiver or informal carer is not used to ICT tools or 
has physical incapability to use them.
5. Presence of intellectual developmental disability.
Some patients may be considered pseudo-resistant to treatment.22 In this case, presence of active symptoms may be influenced by 
psychiatric and medical conditions such as social isolation, consumption of toxic substances, presence of nutritional and medical problems, 
inappropriate health habits which may substantially contribute to poor responses or insufficient effects of medication. Data regarding these 
conditions will be collected.
Patients  having at least two failed adequate trials with different antipsychotics (at chlorpromazine-equivalent doses of ≥600  mg/day  for 
≥6  consecutive  weeks) as well as scores of  ≥4 on the Clinical Global Impression-Severity (CGI-SCH) and ≤50  on the  Global Assessment 
of Functioning (GAF) scales OR patients  with clozapine ongoing treatment due to meeting treatment-resistant criteria as well as scores 
of  ≥4  on the CGI-SCH and  ≤50 on the GAF scale.
*Operational definition of treatment-resistant schizophrenia, modified from Suzuki and colleagues.21
DSM-V, Diagnostic and Statistical Manual of Mental Disorders; ICT, information and communications technology; TRS, treatment-resistant 
schizophrenia. 
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coping strategies and exchange messages with their care-
giver or healthcare provider.
The wearable is a smartwatch that will collect data from 
patients and send it wirelessly to the smartphone. Sensor 
data will be recorded through automatic passive upload. 
The variables collected will be level of activity, heart rate, 
sleeping pattern and steps counter.
The web-based platform is the tool that the healthcare 
providers (case manager, psychiatrist and psychologist) 
will use to collect assessment data, to monitor patients’ 
state and review data collected by sensors, to communi-
cate by texting with patients, caregivers and other profes-
sionals, and to consult recommendations (based on 
guidelines and experts’ opinion).
The m-RESIST intervention has been designed in order 
to meet the following assumptions:
It focuses on key problems: before starting the m-RESIST 
intervention, the patient’s early EWSs and current prob-
lems will be assessed. There will be two outputs. First, the 
patient’s relapse signature configured by the three main 
EWSs presented by the patient before a worsening occurs. 
Each EWS will be linked with a predefined (based on 
CBT) or tailored (based on patient’s experience) coping 
strategy. These strategies will be triggered as a recommen-
dation through the app when patients express distress or 
the system detects risk of worsening. The second output 
will be the treatment plan which will identify the three 
main problems and corresponding goals in the patient’s 
Figure 1 mHealth tools of the m-RESIST solution. m-RESIST, mobile therapeutic attention for treatment-resistant 
schizophrenia. 
Table 2 m-RESIST modules of intervention
Type of 
interversion Basal intervention Risk intervention
Aim Oriented to develop abilities to deal with 
symptoms and early warning signs, to reinforce 
the involvement in the treatment plan, and to solve 
problems influenced by an unhealthy lifestyle.
Oriented to deal with possible situations of worsening 
(eg, detection of risk behaviours).
Modules Integrated by three modules: symptoms 
management, treatment adherence and healthy 
lifestyle.
Integrated by one module: risk.
Core elements Relapse signature identification, coping strategies 
selection.
Risk scale.
Activation 
triggers
External trigger: any of the modules can be 
activated by clinicians through the web-based 
platform (m-RESIST dashboard).
Internal trigger: when the system itself detects risk 
situations such as significant changes in threshold of 
specific sensor data.
External trigger: patients or caregivers ask for help by 
the app’s alarm bottom.
Actions involved Delivery of a basic set of questions by the app, to 
measure patients’ clinical status and appropriate 
follow-up questions or recommendations depending 
on the patients’ answers; use of reminders and 
psychoeducational content to help patients.
Delivery of appropriate questions, to check 
patient’s current condition and to send specific 
recommendations messages or notifications depending 
on the patients’ answers (by the app).
m-RESIST, mobile therapeutic attention for treatment-resistant schizophrenia. 
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life, and link these goals with a specific module of inter-
vention. This process will be agreed between patient, 
caregiver and clinician.
It is modular and tailored to the patient’s condition: two 
categories of interventions have been designed, basal 
and risk intervention (see definition and characteristics 
in table 2). They are related with the list of problems 
mentioned previously, in order to set the most appro-
priate intervention depending on the patient’s situation.
It is capable of detecting worsening: the m-RESIST inter-
vention is capable of changing the system’s triggers to 
patients when worsening is detected by means of the base-
line sensor and clinical profiles. During a 15-day period, 
the patients will use the smartwatch and the smartphone 
to capture continuously multidimensional sensor data. 
The baseline sensor profile will be based on the analyses 
of these data. Furthermore, a complete assessment of 
clinical variables (eg, symptoms, risk behaviours, func-
tionality and adherence) will also be performed in this 
period. The baseline clinical profile will be based on the 
analysis of these data. A set of predefined algorithms 
will detect significant changes in predefined thresholds, 
and trigger specific questionnaires, recommendations 
and notifications. Whenever a moderate or high risk of 
an oncoming episode of worsening is detected, the clin-
ical team will be alerted, and the patient will be offered 
tailored recommendations or emergency assistance.
Concomitant therapy: Apart from the intervention asso-
ciated with the m-RESIST solution, patients will keep 
receiving their treatment-as-usual (including outpatient 
case management, linkage to services and medication 
monitoring). If it is necessary to make changes in the 
psychiatric treatment, they will be recorded in the patient 
profile created in the platform.
outcomes
The evaluation framework to understand the factors 
affecting the user experience and acceptance of the m-RE-
SIST solution among various stakeholders, as well as the 
main determinants affecting user experience at a feasibility 
level, will follow the living lab approach.24 It is defined as ‘a 
user-centric research methodology for sensing, prototyping, 
validating and refining complex solutions in multiple and 
evolving real-world contexts’. Living lab research goes 
beyond mere usability studies and acceptance studies, as it 
also takes the impact of the context of use into account. A 
Table 3 Schedule of study protocol periods and assessments
Activity/assessment
Study periods and visits
Recruitment Preintervention Intervention Follow-up
V0 V1 V2 V3 V4 V5 V6 V7
Eligibility screen X
Informed consent X
Delivery and training of devices X
Sociodemographic data X
Clinical characteristics X
Relapse signature and treatment plan X
Willingness to enrol X
Attrition X X X X X X X X
TAM27 X
User Experience Questionnaire X X X X
Interval Question X X X X X X X
CSQ-828 X
PANSS29 X X
CDS30 X X
SUMD32 X X
ARMS33 X X
CGI-SCH31 X X X X X X X X
GAF34 X X
SFS35 X X
EQ-5D36 X X
Economic and organisational outcomes X X
Safety measures X X X X X X X X
ARMS, Adherence to Refills and Medications Scale; CDS, Calgary Depression Scale; CGI-SCH, Clinical Global Impression-Schizophrenia; 
CSQ-8, Client Satisfaction Questionnaire 8; EQ-5D, EuroQol 5 dimensions; GAF, Global Assessment of Functioning; PANSS, Positive and 
Negative Syndrome Scale; SFS, Social Functioning Scale; SUMD, Scale Unawareness Mental Disorders; TAM, Technology Acceptance 
Model scale. 
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multimethodological approach, with both qualitative and 
quantitative methodologies, is chosen so as to be able to 
capture different aspects of the implemented solution.
The protocol diagram based on SPIRIT guideline20 
provides an overview of the measures used in the trial and 
their time points (see table 3). In addition to outcomes 
described in table 3 and below, sociodemographic and 
clinical characteristics (eg, years of evolution, past and 
current treatment, comorbidities) will be collected by 
using a semistructured interview.
The primary and secondary outcomes (see table 4) of 
the study protocol are the following:
Primary outcomes
The primary outcomes include feasibility and accept-
ability of using the m-RESIST solution. Qualitative and 
quantitative feedback will be collected to identify the 
main determinants of experience and acceptance of the 
m-RESIST solution.
Table 4 Baseline assessment and outcome measures
Measure Definition Data source
Baseline assessment
  Sociodemographic and clinical 
characteristics
Variables such as years of evolution, past and 
current treatment and comorbidities will be 
collected.
Patient interview at baseline
Primary outcomes
  Willingness to enrol The proportion of patients approached about 
the study that proceed to the consent stage.
Protocol database
  Dropout attrition The proportion of participants that fails to 
complete the study.
Protocol database
  Non-usage attrition The proportion of participants that does not 
drop out (eg, who are still completing the 
follow-up), but who stop using the m-RESIST 
tools (smartwatch, app).
Protocol database
  Compliance Variables such as logins, time online and 
questionnaires completed will be collected.
Protocol database
  Acceptability TAM. Patient/caregiver interview at the end of 
study
  Usability User Experience Questionnaire.
Interval Question.
Patient/caregiver/clinician interview 
throughout the study
  Satisfaction CSQ-8. Patient/caregiver interview at the end of 
study
Secondary outcomes
  Severity of symptoms PANSS, CDS. Patient interview at baseline and at the 
end of study
CGI-SCH. Patient interview throughout the duration 
of the study
  Insight SUMD. Patient interview at baseline and at the 
end of study  Adherence ARMS.
  Functionality GAF, SFS.
  Perceived quality of life EQ-5D-5L.
  Economic and organisational 
outcomes
Questionnaires with open ad-hoc questions 
form and semistructured interviews.
Central hospital database queried at 
3 months before recruitment and at the 
end of the study
  Safety The presence of serious and non-serious 
adverse events, defined as any clinical change 
or illness reported during the study, will be 
monitored in every clinical visit.
Patient interview throughout the duration 
of the study
ARMS, Adherence to Refills and Medications Scale; CDS, Calgary Depression Scale; CGI-SCH, Clinical Global Impression-Schizophrenia; 
CSQ-8, Client Satisfaction Questionnaire 8; EQ-5D-5L, EuroQol 5 dimensions 5 levels questionnaire; GAF, Global Assessment of Functioning; 
m-RESIST, mobile therapeutic attention for treatment-resistant schizophrenia; PANSS, Positive and Negative Syndrome Scale; SFS, Social 
Functioning Scale; SUMD, Scale Unawareness Mental Disorders; TAM, Technology Acceptance Model scale. 
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Feasibility will be examined by analysing willingness to 
enrol, attrition and compliance. The measures and oper-
ational criteria are as follows:
 ► Willingness to enrol: the proportion of patients 
approached about the study that proceed to the 
consent stage. Operational criteria definition: ≥70% 
of patients approached will agree to enrol.
 ► Attrition25 26: two measures will be collected, dropout 
and non-usage attrition.
 – Dropout attrition: proportion of participants who 
fail to complete the study protocol and thus do not 
complete the study assessments. Operational crite-
ria definition: <15% of participants will be lost to 
follow-up or withdraw from the study.
 – Non-usage attrition: proportion of participants 
who do not drop out (eg, who are still completing 
the follow-up), but who stop using the m-RESIST 
tools (smartwatch, app). Operational criteria defi-
nition: <15% of participants will stop using devices
 ► Compliance: extent to which participants experience 
the content of the m-RESIST intervention, measured 
by number of logins, time spent online, number 
of questionnaires completed, number of messages 
sent and answered and number of successful 
appointments.
Acceptability of the m-RESIST solution will be assessed in 
terms of acceptability, usability and satisfaction in patients 
with TRS, caregivers and clinicians. Critical measures are 
the following:
 ► Acceptability: a modified version of the Technology 
Acceptance Model (TAM) scale,27 adapted to 
patients with TRS by the research team, will be used. 
The following variables will be evaluated: perceived 
usefulness, perceived ease of use, intention, compat-
ibility, subjective norm, facilitators and habit. Each 
variable is composed of a series of Likert-type items 
(seven levels, from ‘totally disagree’ to ‘totally 
agree’). Data will be collected at the end of the inter-
vention (V7).
 ► Usability: two instruments will be used, User Experi-
ence Questionnaire and Interval Question. The User 
Experience Questionnaire will be delivered by online 
data collection (Qualtrics software) and is composed 
of a combination of survey questions (4-point Likert-
type scale) and open questions. The survey will explore 
perceived ease of use, perceived usefulness, attitude 
and perceived quality of content. The open questions 
will explore lasting impressions and recommenda-
tions. The participants will be asked to complete the 
questionnaire on three occasions during the 3-month 
intervention: at the start (V0), in the middle (V3) and 
at the end of the intervention (V7).
 ► The Interval Question, aimed at better capturing a 
more constant experience of the participants, will ask 
always the same question: What is it like to use the m-RE-
SIST solution? It will be sent to participants via m-RE-
SIST message system once a week, but on different 
days and at different times.
 ► Satisfaction: this variable will be assessed using the 
Client Satisfaction Questionnaire-8.28 This instrument 
will be completed at the end of the intervention (V7).
Secondary outcomes
A complete clinical and economic evaluation would 
be premature in this feasibility study, due to the small 
sample. However, it will be useful to collect necessary 
parameters for planning a full prospective RCT to test 
the cost-effectiveness of m-RESIST solution.
Completion rates and missing data will be explored. 
Operational criteria definition for missing data: <10% of 
each set of secondary outcomes is missed during study 
data collection.
The measures for clinical, functional, quality of life 
and economic outcomes are the following:
Clinical outcomes
 ► Severity of symptoms will be assessed using the 
instruments Positive and Negative Syndrome Scale 
(PANSS),29 Calgary Depression Scale (CDS)30 and 
Clinical Global Impression-Schizophrenia (CGI-
SCH).31 PANSS and CDS will be completed on two 
occasions, at the start (V0) and at the end (V7) of the 
intervention. CGI-SCH will be rated in all protocol 
visits (V0–V7).
 ► Insight will be assessed using the instrument Scale 
Unawareness Mental Disorders.32 This scale will be 
administered on two occasions, at V0 and at V7.
 ► Adherence will be assessed using the Adherence to 
Refills and Medications Scale.33 This instrument will 
be administered on two occasions, at V0 and at V7.
Functional and perceived quality of life outcomes
 ► Functionality will be assessed using the instruments 
Global Assessment of Functioning (GAF)34 and Social 
Functioning Scale (SFS).35 GAF and SFS will be admin-
istered on two occasions, at V0 and at V7.
 ► Perceived quality of life will be assessed using the 
EuroQol 5 dimensions 5 levels questionnaire.36 This 
instrument will be administered on two occasions, at 
V0 and at V7.
Economic and organisational outcomes
Questionnaires with open ad-hoc questions and semi-
structured interviews will be used to assess the use of 
resources (eg, unit cost of personnel of remote or face-to-
face visits, number of emergency admissions and length 
of stay) and the impact of m-RESIST in organisation (ques-
tions regarding effects on the structure, work process and 
the culture of the organisation). This information will be 
gathered at V0 and V7.
Safety measures
Finally, safety measures will also be collected throughout the 
study. The presence of serious and non-serious adverse 
events, defined as any clinical change or illness reported 
during the study, will be monitored in every clinical visit. 
The adverse events observed when carrying out the study, 
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either by the clinician or by the patient himself/herself 
and regardless of the causality relationship ascribed, will 
be recorded in the clinical records and at the patient’s 
dashboard.
Participant timeline
The study will consist of four periods: recruitment, prein-
tervention, intervention and follow-up.
1. Recruitment period, aimed at contacting and checking 
the eligibility of candidates. The outputs of an in-depth 
report about healthcare routes and clinical pathways in 
the three participant regions, made within the context 
of the m-RESIST project, have helped to identify the 
strengths and weakness of the recruitment capabilities. 
In order to reach the total sample of participants, two 
recruitment strategies will be used. Leaflets to promote 
the study will be distributed to healthcare providers, 
informing them about the study and inviting them to 
contact the research staff if potential participants are 
identified. In addition, research staff at the recruit-
ment sites will approach eligible patients directly to 
suggest participating in the study. Informed consent 
signature for patients with TRS and caregiver will be 
obtained if inclusion and exclusion criteria are met, 
and both patient and caregiver agree to participate in 
the study.
2. Preintervention period (V0), aimed at training the 
participants in using the smartwatch and the app, and 
collecting clinical and sensor baseline information. At 
the beginning of the preintervention period, patients 
will be given the study smartwatch and smartphone, 
with m-RESIST app preinstalled. Caregivers will be 
given permission to install the app in their own smart-
phone. Both will be trained by the research staff in 
how to use the functions of the smartwatch and the 
different features of the app. Research staff will also 
provide patients and caregivers with training material 
(user guide and online video tutorial). Patients will be 
asked to wear the smartwatch for a period of at least 15 
days, in order to collect enough sensor data to estab-
lish the baseline sensor profile. Furthermore, patients 
and caregivers will also be encouraged to use and fa-
miliarise themselves with the app by consulting the ed-
ucational content and using the messaging system. Pa-
tients will also attend a clinical assessment, where sec-
ondary outcomes will be collected (see table 3). At the 
end of the preintervention period, the key elements 
(relapse signature and treatment plan) to deliver a tai-
lored intervention will be explored.
3. Intervention period (V1–V7) aimed at testing the fea-
tures and action flows that configure the m-RESIST 
interventions, and at assessing the experience of par-
ticipants. At the beginning of the intervention, the 
treatment plan will be defined and the corresponding 
basal intervention will be activated. Participants will 
use the solution over 3 months, and appointments with 
clinicians will be scheduled every 15 days. This period 
will comprise four online visits and three onsite visits. 
In each visit, the treatment plan will be reviewed, the 
CGI scale and measure of patients’ perceived health 
status will be assessed and changes in the current an-
tipsychotic treatment and potential adverse events will 
be explored. At the end of this period, a final visit will 
be held, made up of the full global assessment, to get 
post-test measures of the variables assessed in the pre-
intervention period (see table 3).
4. Follow-up period, aimed at evaluating the primary and 
secondary outcomes of the study.
sample size
This protocol study is a non-randomised feasibility study 
where the primary outcomes are not measures of inter-
vention effects, but factors that could affect the successful 
execution of RCT. The proposed sample size of 45 
patients, with their corresponding caregivers, is consis-
tent with the recommendations for feasibility studies.37 38
data analysis
Descriptive statistics (means and SDs or percentages) will 
be used to summarise baseline sociodemographic and 
clinical characteristics of participants.
Analysis of primary outcomes
Descriptive statistics will be used to ascertain feasibility. 
Willingness to enrol and attrition components will be 
summarised for participants, overall and in relation to 
selected baseline characteristics. Differences between 
followed up patients and those who were lost to follow-up 
will be examined in terms of baseline characteristics, by 
a paired sample t-test (normal distribution) or Wilcoxon 
signed-rank test (non-normal distribution).
Quantitative and qualitative data for acceptability and 
usability will be examined:
Quantitative data: each variable measured in acceptability 
and usability configured a Likert scale. The composite 
score (mean) of each variable will be calculated and 
treated as an interval/ratio scale. Pearson correlations 
between the constructs will be calculated to explore the 
following hypotheses: perceived usefulness and perceived 
ease of use is positively and significantly correlated to atti-
tude; perceived ease of use is positively and significantly 
correlated to perceived usefulness; perceived quality of 
content will influence perceived usefulness and ease of 
use. Repeated measures of the User Experience Ques-
tionnaire will be tested by repeated measures analysis of 
variance method.
Qualitative data: for the analysis of self-reported data 
collected from User Experience Questionnaire and from 
Interval Question, qualitative thematic/content analysis 
will be conducted as proposed by Mayring.39 This method 
is a technique of summarisation, whereby themes are 
created in an inductive procedure by reducing, para-
phrasing and generalising relevant text passages. Patterns 
in the text will be found and coded in order to search for 
themes in the data. The data will be subjected to thematic 
content analysis with the help of Atlas-ti software.
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Finally, descriptive statistics will be used to assess satis-
faction with m-RESIST intervention.
Analysis of secondary outcomes
Descriptive statics will be used to explore the availability and 
utility of data relating to proposed clinical, functional and 
economic outcomes measures, and a range of summary 
measures will be presented in the final statistical outputs.
Statistical analysis
Analyses will be conducted using STATA V.13. Descriptive 
statistics will be used to summarise clinical and demo-
graphic characteristics of patients. Feasibility of trial proce-
dures will be examined using proportions and 95% CIs 
for assessments of feasibility and acceptability in terms of 
recruitment, consent, dropout, follow-up and integrity of 
double blinding. The variance observed in this sample will 
be used for sample size calculation for the future RCT, as 
recommended by Lancaster and colleagues.40
Quality control
The researcher will ensure the accuracy and integrity of the 
data and reports required. The data included in the m-RE-
SIST derived from source documents will be consistent with 
such documents; otherwise, the discrepancies will be justi-
fied. The researcher will keep the study documents for at 
least 5 years after the study is completed.
Data monitoring will be done by the ethics committee of 
each site. Clinicians will have all the study-related files avail-
able, allowing direct access to data or source documents to 
perform monitoring, audit, review by the ethics committee 
or any inspection by the competent authorities. All data 
collected will only be accessible to m-RESIST partners.
EthICs And dIssEMInAtIon
Before entering the study, all participants will be legally 
competent and will provide written informed consent 
to the clinical team. All the data collected will be treated 
confidentially and analysed anonymously. Any protocol 
amendments will be made through the ethics committee 
of each site. The results of this study will be published in 
international peer-reviewed journals. A wide dissemination 
of the project results is planned to take place at European 
and international level. Patients, caregivers, health profes-
sionals, institutions and stakeholders will be targeted as the 
main recipients of the m-RESIST outcomes.
study stAtus
At the time of writing, the m-RESIST solution was still 
being tested by technological and clinical partners 
belonging to the project’s consortium, and potential 
participants were being assessed.
dIsCussIon
This article summarises the protocol of a multicentre 
feasibility study aimed at assessing rates of attrition and 
acceptability of the m-RESIST solution. This information 
will provide important parameters to consider running a 
cost-effective RCT, and to identify potential constraints 
and possible solutions.
TRS is a complex phenomenon usually excluded from 
RCT. Our research group, made up of experienced clini-
cians and researchers in TRS  patient follow-up, is inter-
ested in understanding the factors that lead to resistance 
or response in this patient population, and in developing 
new approaches to treatment.
The m-RESIST project targets the ‘high end’ (in terms 
of severity) of psychiatric morbidity–TRS, which is char-
acterised by a chronic and continuous prolonged course, 
low level of adherence, insight and judgement, and is 
particularly challenging also due to impairments in inter-
personal communication. These challenges reduce the 
possibility of the patients’ taking full responsibility for 
their treatment and self-care, and communicating their 
needs and changes in clinical state. The TRS multidimen-
sional presentation, diverse course and multidimensional 
functioning impairment require treating patients with 
TRS by a multidimensional approach, including multidis-
ciplinary teamwork and different interventions.
Current trends in treating schizophrenia result from general 
social trends and recent developments in medical care, 
including implementation of evidence-based medicine 
tools and novel technological developments in the field 
of healthcare, specifically regarding data collection using 
various sensors, data processing and communication. 
Healthcare systems are also moving towards person-
alised medicine, combining a large body of personal and 
disease-related information. The aforementioned view 
of heterogeneous complicated needs of patients with 
TRS, their caregivers and treating clinicians emphasises 
the need for a comprehensive system that will allow and 
encourage different modes of communication between 
potential users involved in the clinical complexity of the 
disease.
The m-RESIST solution is an initiative targeted to 
create a hybrid system aimed at optimisation of chronic 
care by integrating technological solutions, and assisting 
clinicians in their decision-making process. The devel-
oped solution also enhances the involvement of patients 
in their own treatment process, encouraging active partic-
ipation in therapeutic processes, self-managing of their 
condition, thus reinforcing a sense of empowerment and 
improving quality of life.
The novel principles include new technology, high modu-
larity and flexibility, and personalised response to heter-
ogenic needs. In order to overcome the disadvantages 
of the current healthcare system, the m-RESIST solution 
intends to provide continuity of care, immediate atten-
tion for prevention of worsening and hospitalisations, 
automated and personalised interventions and recom-
mendations, as well as easy and efficient communication 
between the solution users.
The main limitations of the study are those character-
istic of feasibility studies, the lack of randomisation and a 
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control group. It may have a high dropout rate, so predic-
tors of discontinuation should be assessed comparing 
characteristics of compliant patients with those who were 
lost to follow-up. Furthermore, studies in mHealth require 
a minimum range of skills to use the tools. In this regard, 
patients with TRS can present limitations in using the 
devices due to some degree of cognitive impairment, and 
caregivers might have a poor knowledge of the internet, 
computer and other devices due to their age range.
However, and despite the aforementioned limitations, 
the findings and outputs from the proposed study will 
take us closer to designing a future cost-effectiveness trial 
in treatment-resistant patients.
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